[
    [
        {
            "time": "",
            "original_text": "一财研选｜阿里腾讯巨资参与万达私有化，“新零售”站上行业风口！",
            "features": {
                "keywords": [
                    "阿里",
                    "腾讯",
                    "万达",
                    "私有化",
                    "新零售"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "零售",
                    "科技",
                    "房地产"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "一财研选｜阿里腾讯巨资参与万达私有化，“新零售”站上行业风口！",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "[领先大市-A评级]医药行业每周观点：控费仍是主旋律 从医保支付结构改善角度寻求投资机会",
            "features": {
                "keywords": [
                    "医药",
                    "控费",
                    "医保",
                    "支付结构",
                    "投资机会"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "[领先大市-A评级]医药行业每周观点：控费仍是主旋律 从医保支付结构改善角度寻求投资机会",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "[买入评级]医药生物行业景气度前瞻之二：医药外包：春江水暖鸭先知",
            "features": {
                "keywords": [
                    "医药生物",
                    "景气度",
                    "医药外包"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "[买入评级]医药生物行业景气度前瞻之二：医药外包：春江水暖鸭先知",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]